中国医药
中國醫藥
중국의약
China Medicine
2015年
12期
1828-1831
,共4页
徐海波%吴霞%陆云燕%李铃铃
徐海波%吳霞%陸雲燕%李鈴鈴
서해파%오하%륙운연%리령령
卵巢肿瘤%铂类耐药%复发%伊立替康%奥沙利铂
卵巢腫瘤%鉑類耐藥%複髮%伊立替康%奧沙利鉑
란소종류%박류내약%복발%이립체강%오사리박
Ovarian neoplasms%Platinum resistance%Recurrence%Irinotecan%Oxaliplatin
目的 探讨伊立替康联合奥沙利铂对铂类耐药型复发卵巢癌的治疗效果.方法 回顾性分析2009年7月至2012年7月就诊于江苏省南通市肿瘤医院妇瘤科的铂类耐药型复发卵巢癌患者56例,患者均接受伊立替康联合奥沙利铂方案化疗,观察近远期疗效及化疗相关不良反应.结果 56例患者中,完全缓解1例(1.8％)(该患者治疗前CT及体检均未见肿块,化疗2个周期后指标正常,共化疗6个周期,随访14个月后再次复发),部分缓解16例(28.6％),稳定21例(37.5％),有效率为30.4％ (17/56),疾病控制率为67.9％(38/56);中位疾病无进展生存时间为7.0(95％置信区间:5.6 ～8.4)个月,中位整体生存时间为16.0(95％置信区间:13.0～19.0)个月.化疗相关不良反应依次为中性粒细胞减少[67.9％(38/56)]、神经毒性[60.7％(34/56)]、恶心呕吐[57.1％ (32/56)]、迟发性腹泻[55.4％ (31/56)]、乙酰胆碱能综合征[21.4％ (12/56)]、肝肾功能异常[14.3％ (8/56)]、贫血[7.1％ (4/56)]、血小板减少[7.1％ (4/56)];有3例患者因不良反应而延迟用药;所有患者均未出现化疗相关性死亡.结论 伊立替康联合奥沙利铂治疗铂类耐药型复发卵巢癌安全有效.
目的 探討伊立替康聯閤奧沙利鉑對鉑類耐藥型複髮卵巢癌的治療效果.方法 迴顧性分析2009年7月至2012年7月就診于江囌省南通市腫瘤醫院婦瘤科的鉑類耐藥型複髮卵巢癌患者56例,患者均接受伊立替康聯閤奧沙利鉑方案化療,觀察近遠期療效及化療相關不良反應.結果 56例患者中,完全緩解1例(1.8％)(該患者治療前CT及體檢均未見腫塊,化療2箇週期後指標正常,共化療6箇週期,隨訪14箇月後再次複髮),部分緩解16例(28.6％),穩定21例(37.5％),有效率為30.4％ (17/56),疾病控製率為67.9％(38/56);中位疾病無進展生存時間為7.0(95％置信區間:5.6 ～8.4)箇月,中位整體生存時間為16.0(95％置信區間:13.0～19.0)箇月.化療相關不良反應依次為中性粒細胞減少[67.9％(38/56)]、神經毒性[60.7％(34/56)]、噁心嘔吐[57.1％ (32/56)]、遲髮性腹瀉[55.4％ (31/56)]、乙酰膽堿能綜閤徵[21.4％ (12/56)]、肝腎功能異常[14.3％ (8/56)]、貧血[7.1％ (4/56)]、血小闆減少[7.1％ (4/56)];有3例患者因不良反應而延遲用藥;所有患者均未齣現化療相關性死亡.結論 伊立替康聯閤奧沙利鉑治療鉑類耐藥型複髮卵巢癌安全有效.
목적 탐토이립체강연합오사리박대박류내약형복발란소암적치료효과.방법 회고성분석2009년7월지2012년7월취진우강소성남통시종류의원부류과적박류내약형복발란소암환자56례,환자균접수이립체강연합오사리박방안화료,관찰근원기료효급화료상관불량반응.결과 56례환자중,완전완해1례(1.8％)(해환자치료전CT급체검균미견종괴,화료2개주기후지표정상,공화료6개주기,수방14개월후재차복발),부분완해16례(28.6％),은정21례(37.5％),유효솔위30.4％ (17/56),질병공제솔위67.9％(38/56);중위질병무진전생존시간위7.0(95％치신구간:5.6 ～8.4)개월,중위정체생존시간위16.0(95％치신구간:13.0～19.0)개월.화료상관불량반응의차위중성립세포감소[67.9％(38/56)]、신경독성[60.7％(34/56)]、악심구토[57.1％ (32/56)]、지발성복사[55.4％ (31/56)]、을선담감능종합정[21.4％ (12/56)]、간신공능이상[14.3％ (8/56)]、빈혈[7.1％ (4/56)]、혈소판감소[7.1％ (4/56)];유3례환자인불량반응이연지용약;소유환자균미출현화료상관성사망.결론 이립체강연합오사리박치료박류내약형복발란소암안전유효.
Objective To investigate the effect of irinotecan combined with oxaliplatin in treatingplatinum-resistant recurrent ovarian cancer.Methods A total of 56 patients with platinum-resistant recurrent ovarian cancer who were treated with irinotecan combined with oxaliplatin regimen were retrospectively analyzed.The curative effect and chemotherapy-associated side effects were observed.Results One patient (1.8％)achieved complete remission (CT and physical examination showed no tumor, 6 cycles of chemotherapy were performed and the related indices returned to normal after 2 cycles, the tumor reappeared 14 months later);16 eases (28.6％) achieved partial remission, 21 patients (37.5％) achieved stable disease.The total effective rate was 30.4％ (17/56) and the disease control rate was 67.9％ (38/56).The median progression free survival time was 7.0 months (95％ CI: 5.6-8.4), the median survival time was 16 months (95％ CI: 13.0-19.0).The common adverse reactions included myelosuppression [67.9％ (38/56)], neurotoxin [60.7％ (34/56)],nausea and vomiting [57.1％ (32/56)], delayed diarrhea [55.4％ (31/56)], acetylcholine syndrome [21.4％ (12/56)], abnormal liver and kidney function [14.3％ (8/56)], anaemia [7.1％ (4/56)],thrombocytopenia [7.1％ (4/56)];the therapy was delayed in 3 cases because of adverse reactions;there was no chemotherapy related death.Conclusion Irinotecan combined with oxaliplatin regimen is safe and effective in treating platinum-resistant recurrent ovarian cancer.
